Immunomedics Provides Clinical Updates on Breast Cancer Programs With Sacituzumab Govitecan

- December 6th, 2018

Immunomedics (NASDAQ:IMMU) a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today presents updated Phase 2 results at the 2018 SABCS, confirming that monotherapy with sacituzumab govitecan achieved an objective response rate (ORR) of over 30 percent among heavily pre-treated patients with metastatic triple-negative breast cancer (mTNBC), with a manageable safety profile. As quoted in … Continued

Immunomedics (NASDAQ:IMMU) a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today presents updated Phase 2 results at the 2018 SABCS, confirming that monotherapy with sacituzumab govitecan achieved an objective response rate (ORR) of over 30 percent among heavily pre-treated patients with metastatic triple-negative breast cancer (mTNBC), with a manageable safety profile.

As quoted in the press release:

“We believe these results show that sacituzumab govitecan can be a viable treatment option and help alleviate the unmet need in mTNBC,” stated Dr. Robert Iannone, Head of R&D and Chief Medical Officer of Immunomedics. “We have shared these updates with the FDA during its ongoing priority review of our Biologics License Application for accelerated approval of sacituzumab govitecan in metastatic TNBC.”

Treatment with sacituzumab govitecan was well tolerated, with a predictable and manageable safety profile, and low discontinuation rates due to adverse events. The most relevant adverse events were gastrointestinal and neutropenia, which were manageable with routine supportive care per general practice guidelines.

Click here to read the full press release.

Are gold stocks a good idea for 2019?


Get your free market forecast today

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select All
Select None

By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time

Leave a Reply

Your email address will not be published. Required fields are marked *